Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Investor's Business Daily on MSN3h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...
We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...
The Motley Fool on MSN13d
Is Merck Stock a Buy?In my view, based on what's coming up for Merck, it's likely that investors with some patience will find the stock to be more appealing. Understanding the investment thesis for Merck requires ...
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback